NECTIN4 and neoplasm: Short course treatment with rosiglitazone did not alter RT112 tumor xenograft growth when compared to vehicle plus NTD T cells (Fig. 4e), suggesting that rosiglitazone alone does not affect RT112 tumor xenograft growth, but does enhance NECTIN4-CAR T cell efficacy and overall survival (Fig. 4e, f).